Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

Ignyta, Inc. (RXDX) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/08/2018 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Amended and Restated Certificate of Incorporation of Ignyta, Inc",
"Amended and Restated Bylaws of Ignyta, Inc",
"Roche purchases shares in tender offer for Ignyta, Inc. Roche and Ignyta, Inc. today announced that Roche's wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Ignyta, Inc. at a price of USD 27.00 per share in cash. The tender offer expired at 12:00 midnight, Eastern Time, at the end of the day on 7 February 2018 and was not extended. Roche has been advised by Citibank, N.A., the depositary for the tender offer, that a total of approximately 57,372,887 shares of Ignyta's common stock were validly tendered and not validly withdrawn in the tender offer , which represent approximately 84.71% of the total number of shares of Ignyta's common s..."
12/28/2017 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Agreement, between Ignyta, Inc. and Jonathan Lim, M.D",
"Agreement, between Ignyta, Inc. and Jonathan Lim, M.D"
12/22/2017 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 21, 2017 IGNYTA, INC. Delaware 001-36344 45-3174872 4545 Towne Centre Court San Diego, California 92121 Registrant's telephone number, including area code: 255-5959",
"Agreement and Plan of Merger, by and among Ignyta, Inc., Roche Holdings, Inc. and Abingdon Acquisition Corp",
"Tender and Support Agreement, by and among Roche Holdings, Inc., Abingdon Acquisition Corp. and certain stockholders of Ignyta, Inc",
"Roche and Ignyta reach definitive merger agreement"
11/07/2017 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 7, 2017 IGNYTA, INC. Delaware 001-36344 45-3174872 4545 Towne Centre Court San Diego, California 92121 Registrant's telephone number, including area code: 255-5959 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communic...",
"Ignyta Announces Third Quarter 2017 Company Highlights and Financial Results November 7, 2017, 4:00 PM Eastern Time SAN DIEGO—— Ignyta , Inc. , a biotechnology company focused on precision medicine in oncology, today announced company highlights and financial results for the third quarter ended September 30, 2017. The company is issuing this press release in lieu of conducting a conference call. “We are pleased with the continued development and regulatory progress of our lead product candidate, entrectinib —an investigational, CNS-active, potent, and selective tyrosine kinase inhibitor being developed for tumors that harbor TRK or ROS1 fusions—as we approach the expected submission of two NDAs and a PMA in 2018.” said Jonathan Lim, M.D., Chairman and CEO of Ignyta. “In addition, during th..."
10/20/2017 8-K Quarterly results
10/18/2017 8-K Quarterly results
10/17/2017 8-K Quarterly results
09/11/2017 8-K Quarterly results
09/06/2017 8-K Quarterly results
08/18/2017 8-K Quarterly results
08/08/2017 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Ignyta Announces Second Quarter 2017 Company Highlights and Financial Results"
06/15/2017 8-K Form 8-K - Current report
06/07/2017 8-K Form 8-K - Current report
05/16/2017 8-K Form 8-K - Current report
05/09/2017 8-K Form 8-K - Current report
05/01/2017 8-K Form 8-K - Current report
04/27/2017 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"IGNYTA UPDATES PROGRESS TOWARDS ENTRECTINIB DUAL TRK AND ROS1 NDA SUBMISSIONS",
"Investor Presentation, made April 27, 2017"
04/04/2017 8-K Form 8-K - Current report
03/30/2017 8-K Form 8-K - Current report
03/23/2017 8-K Form 8-K - Current report
03/14/2017 8-K Form 8-K - Current report
02/15/2017 8-K Form 8-K - Current report
02/09/2017 8-K Form 8-K - Current report
01/11/2017 8-K Form 8-K - Current report
01/09/2017 8-K Form 8-K - Current report
12/23/2016 8-K Form 8-K - Current report
12/12/2016 8-K Form 8-K - Current report
12/02/2016 8-K Form 8-K - Current report
12/01/2016 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "IGNYTA ANNOUNCES COMPELLING PHASE 1/1b CLINICAL DATA ON RXDX-105, ITS VEGFR-SPARING RET INHIBITOR, AT THE 2016 EORTC-NCI-AACR ANNUAL MEETING",
"Investor Presentation, made December 1, 2016"
11/29/2016 8-K Form 8-K - Current report
11/07/2016 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Ignyta Announces Third Quarter 2016 Company Highlights and Financial Results"
08/09/2016 8-K Form 8-K - Current report
07/01/2016 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Warrant dated June 30, 2016, issued to Silicon Valley Bank",
"Warrant dated June 30, 2016, issued to Silicon Valley Bank",
"Warrant dated June 30, 2016, issued to Oxford Finance LLC",
"Warrant dated June 30, 2016, issued to Oxford Finance LLC",
"Warrant dated June 30, 2016, issued to Oxford Finance LLC",
"Warrant dated June 30, 2016, issued to Oxford Finance LLC",
"Warrant dated June 30, 2016, issued to Oxford Finance LLC",
"Warrant dated June 30, 2016, issued to Oxford Finance LLC",
"Warrant dated June 30, 2016, issued to Oxford Finance LLC",
"Warrant dated June 30, 2016, issued to Oxford Finance LLC"
06/15/2016 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy